Co-Authors
This is a "connection" page, showing publications co-authored by Hualiang Jiang and Yechun Xu.
Connection Strength
1.669
-
Potential treatment of COVID-19 by inhibitors of human dihydroorotate dehydrogenase. Protein Cell. 2020 10; 11(10):699-702.
Score: 0.906
-
Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease. Nat Commun. 2021 06 15; 12(1):3623.
Score: 0.238
-
Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol Sin. 2020 Sep; 41(9):1167-1177.
Score: 0.224
-
A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors. Acta Pharmacol Sin. 2022 Feb; 43(2):483-493.
Score: 0.059
-
Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2. J Med Chem. 2022 02 24; 65(4):2794-2808.
Score: 0.059
-
Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science. 2020 06 26; 368(6498):1499-1504.
Score: 0.055
-
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020 06 19; 368(6497):1331-1335.
Score: 0.055
-
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020 06; 582(7811):289-293.
Score: 0.055
-
pH-dependent conformational flexibility of the SARS-CoV main proteinase (M(pro)) dimer: molecular dynamics simulations and multiple X-ray structure analyses. J Mol Biol. 2005 Nov 18; 354(1):25-40.
Score: 0.020